AbCellera doses first patients in Phase 2 trial of ABCL635 for menopausal vasomotor symptoms

AbCellera Biologics Inc.

ABCL635, a non-hormonal candidate for moderate-to-severe vasomotor symptoms (VMS) of menopause, advances to Phase 2.
Phase 2 is a randomized, double-blind, placebo-controlled study in 80 postmenopausal women.
Top-line clinical results for both Phase 1 and Phase 2 expected in Q3 2026.
Phase 1/2 redesignation based on interim safety, tolerability, and pharmacodynamic data from healthy volunteers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.